Johnson & Johnson (JNJ) Tops Q3 EPS by 2c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Johnson & Johnson (JNJ) PT Raised to $150 at RBC Capital
October 17, 2018 7:49 AM EDTRBC Capital analyst Glenn Novarro raised the price target on Johnson & Johnson (NYSE: JNJ) to $150.00 (from $143.00) while maintaining an Outperform rating following Q3 results.
Novarro notes Pharma excelled again, and the Devices & Consumer segments are heading in the right direction.
The... More



